New immune cell therapy tested for tough blood cancers
NCT ID NCT07350863
Summary
This is an early-stage study testing a new type of CAR-T cell therapy called CXCR4 CCR9 CAR-T in patients whose T-cell leukemia or lymphoma has come back or hasn't responded to standard treatments. The main goals are to find a safe dose, check for side effects, and get an early look at whether the treatment can shrink the cancer. The study will enroll up to 18 patients who will receive the cell infusion and be followed for safety and response.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY T-LYMPHOBLASTIC LEUKEMIA/LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.